TriSalus Life Sciences, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-129.6M | $200.9K |
| FY2022 | — | $-177.1M | $9.4M |
| FY2023 | $0 | $-27.1M | $11.8M |
| FY2024 | $22.1M | $-25.9M | $8.5M |
| FY2025 | $33.0M | $-33.9M | $20.4M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $-129.6M | $200.9K |
| FY2022 | — | $-177.1M | $9.4M |
| FY2023 | $0 | $-27.1M | $11.8M |
| FY2024 | $22.1M | $-25.9M | $8.5M |
| FY2025 | $33.0M | $-33.9M | $20.4M |